Innovative Therapies for Type 1 Diabetes: Immunotherapy and Beta-Cell Regeneration

Abstract

Diabetes is a chronic condition that disrupts glucose metabolism in the body. As there is no clinical cure available, the condition is managed through medications, insulin therapy, dietary changes, exercise, and other lifestyle adjustments. However, traditional treatments are often limited by their lifelong dependence and reduced effectiveness over time, hindering the patient’s full recovery. This limitation has led to a shift in focus, prompting research into alternative strategies. Since Type 1 diabetes (T1D) is an autoimmune disorder, approaches that target the immune system to either stimulate or suppress its activity have shown promise in reducing beta cell destruction and improving insulin response to high blood sugar. Additionally, the use of nanoparticles to deliver immunomodulators, insulin, or vaccines to immune cells is being explored as a potential therapeutic option. This method of nanoparticle-based targeting offers significant promise for improving T1D care. This review summarizes the current understanding of T1D\'s causes, clinical challenges, and the emerging role of nanoparticle-based therapies. We also evaluate the feasibility of bringing these approaches into clinical practice. Furthermore, stem cell therapy shows potential to restore ?-cell function and reduce reliance on insulin therapy, though its clinical application is still in early stages. Significant progress has been made in preclinical studies, but more research is needed to ensure the safety and effectiveness of stem cell treatments and to prevent immune rejection. This review also examines ongoing research into cellular therapies, including stem cell treatments, gene therapy, immunotherapy, artificial pancreas systems, and cell encapsulation, as well as their potential for clinical use in treating T1D. Immunotherapy-based strategies have recently been integrated into the existing treatments for Type 1 diabetes (T1D) to block T-cell responses against beta cell antigens, which are commonly involved in the onset and progression of T1D. However, achieving complete preservation of beta cell mass and insulin independence remains an unresolved challenge. As a result, no immunotherapy for T1D has yet been developed to replace the need for standard insulin therapy. Currently, several innovative therapeutic approaches are being explored to protect beta cells and achieve normal blood sugar levels. This review examines the current progress in immunotherapy for T1D, highlights key studies in the field, and discusses potential future strategies for treating the condition.[ 1,2,28,29]

Introduction

Diabetes Mellitus Overview:
Diabetes mellitus is an endocrine disorder marked by high blood sugar (hyperglycemia) leading to tissue damage if untreated. It mainly includes Type 1 Diabetes Mellitus (T1DM), an autoimmune disease causing insulin deficiency usually in young individuals, and Type 2 Diabetes Mellitus (T2DM), a metabolic disorder caused by genetic factors and insulin resistance.

Type 1 Diabetes (T1D):
T1D results from the immune system attacking pancreatic beta cells that produce insulin, causing insulin dependence. It typically affects children and young adults and is diagnosed through blood glucose tests. T1D requires lifelong insulin therapy and careful management to prevent complications like cardiovascular disease and neuropathy.

Immune Mechanism in T1D:
The autoimmune destruction involves immune cells attacking pancreatic islets, triggered by genetic predisposition and environmental factors such as infections. Autoantibodies and T cells drive inflammation (insulitis) and beta-cell loss, causing insulin deficiency and complications like diabetic ketoacidosis.

Current Treatments and Challenges:
Standard treatment is insulin replacement, but it doesn’t cure T1D. Oral medications help in T2DM but have limitations.

Emerging Therapies:

• Immunotherapy: Drugs or biologics aim to regulate the immune system to prevent beta-cell destruction, such as anti-CD3 antibodies, IL-2 to boost regulatory T cells, and engineered islet transplantation with immune-evasive modifications.

• Cell-Based Therapy: Transplantation of donor islet or beta cells, gene therapy to enhance beta-cell survival or suppress autoimmunity, and cell encapsulation are under research.

• Gene Therapy: Introducing genes like Pdx-1 or anti-inflammatory cytokines to promote beta-cell function and reduce autoimmunity.

• Stem Cell Therapy: Using pluripotent stem cells to regenerate beta cells is promising but still experimental.

• Beta-Cell Targeted Therapy: Monoclonal antibodies (e.g., Rituximab) target immune cells but have limited success due to side effects and immune resistance.

• Islet Transplantation (Edmonton Protocol): Transplanting donor islets with immunosuppression can achieve insulin independence but faces donor shortage and immune rejection issues.

• Beta-Cell Regeneration: Combination therapies using gastrin and GLP-1 aim to stimulate beta-cell growth, but clinical results are still inconclusive.

Immune System Role:
Activation and regulation of T and B lymphocytes are critical in disease progression. Cytokines like IL-21 promote autoimmunity, while regulatory mechanisms attempt to control it. Targeting these pathways offers potential treatment strategies.

Novel Strategies:
CAR-T cell therapy, engineered T cells that target specific immune cells independent of MHC, represents an innovative approach with potential applications beyond cancer treatment.

Conclusion

The global diabetes epidemic has become a critical health issue, and the absence of effective and comprehensive treatments contributes significantly to the rising prevalence of the condition. Recent advancements in biomedical research have led to the development of various diabetes management and therapeutic strategies (as shown in Fig. 6), including immunotherapy, artificial pancreas, and cell-based therapies, which show great potential in treating diabetes through unique and powerful mechanisms. Immunotherapy works by modulating the immune system to prevent the destruction of ?-cells, thus preserving insulin production. Although early clinical trials have yielded promising results, there remain unresolved questions regarding the best timing, dosage, and duration of immunotherapy, as well as concerns about long-term side effects. The artificial pancreas, which can automatically adjust insulin delivery based on real-time glucose readings, holds promise. However, improvements in glucose sensor accuracy and the optimization of control algorithms are necessary to enhance the effectiveness of the artificial pancreas for diabetes treatment. A variety of therapeutic strategies are being explored for Type 1 Diabetes Mellitus (T1DM), ranging from immunomodulation and transplantation to combinations of these approaches, and even the potential to induce regulatory immune cells and differentiated islet cells in vivo. Biologics, such as antibodies and cytokines, have been used in clinical settings to induce immune tolerance, showing better results than traditional small molecule drugs like steroids. Cellular therapy is a more recent method aimed at providing targeted immune suppression and promoting stem cell-mediated regeneration. Among these, Tregs (regulatory T cells) have gained attention as a potential treatment for T1DM due to their ability to suppress autoimmune responses without causing widespread immunosuppression. However, a major challenge remains in effectively and consistently inducing or expanding Tregs. The main challenges in T1DM treatment lie in improving the patient\'s quality of life and ensuring that the treatments are sustainable over time. While islet transplants and immunosuppressants can be used, the side effects of non-selective small molecule drugs must be considered. If islet encapsulation is chosen as a treatment option, issues such as insulin/nutrient exchange, protection from immune damage, hypoxia, and fibrosis of the capsules need to be addressed. A significant issue with islet encapsulation is that the microencapsulation methods often result in large capsule sizes, which can impair insulin diffusion. This can reduce insulin secretion, increase islet necrosis, and raise the risk of hypoxia. Therefore, preparing suitable implantation sites for the islet capsules, considering the large volume of encapsulated islets or ?-cells, is critical. Other important factors include enhancing capsule and device stability, minimizing the volume and size of the engraftment, and reducing immune responses. Despite advances in new technologies, several obstacles remain. These include the fragility of transplant devices and the potential need for \"refills\" of islets. Additionally, approaches such as immunotherapy using Tregs are becoming more prominent as potential treatments for T1DM. While each treatment option faces challenges, the most important consideration, beyond the effectiveness of any treatment, is the overall well-being and quality of life of the patient.[25,26,27,28,29]

References

[1] Patterson, C.; Guariguata, L.; Dahlquist, G.; Soltesz, G.; Ogle, G.; Silink, M. Diabetes in the young—Aglobal view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res. Clin. Pract.2014, 103, 161–175. [CrossRef] [PubMed] [2] Maahs, D.M.; West, N.A.; Lawrence, J.M.; Mayer-Davis, E.J. Epidemiology of type 1 diabetes. Endocrinol. Metab.Clin. N. Am. 2010, 39, 481–497. [CrossRef] [PubMed] [3] Barrett, J.C.; Clayton, D.G.; Concannon, P.; Akolkar, B.; Cooper, J.D.; Erlich, H.A.; Julier, C.; Morahan, G.;Nerup, J.; Nierras, C.; et al. Genome-wide association study and meta-analysis find that over 40 loci affectrisk of type 1 diabetes. Nat. Genet. 2009, 41, 703–707. [CrossRef] [PubMed] [4] Pociot, F.; Akolkar, B.; Concannon, P.; Erlich, H.A.; Julier, C.; Morahan, G.; Nierras, C.R.; Todd, J.A.; Rich, S.S.;Nerup, J. Genetics of type 1 diabetes: What’s next? Diabetes 2010, 59, 1561–1571. [CrossRef] [PubMed] [5] Nerup, J.; Platz, P.; Andersen, O.O.; Christy, M.; Lyngsoe, J.; Poulsen, J.E.; Ryder, L.P.; Nielsen, L.S.;Thomsen, M.; Svejgaard, A. HL-A antigens and diabetes mellitus. Lancet 1974, 2, 864–866. [CrossRef] [6] Clark, M.; Kroger, C.J.; Tisch, R.M. Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response.Front. Immunol. 2017, 8, 1898. [CrossRef] [PubMed] [7] Shapiro, A.M.; Ricordi, C.; Hering, B.J.; Auchincloss, H.; Lindblad, R.; Robertson, R.P.; Secchi, A.;Brendel, M.D.; Berney, T.; Brennan, D.C.; et al. International trial of the Edmonton protocol for islettransplantation. N. Engl. J. Med. 2006, 355, 1318–1330. [CrossRef] [8] Perseghin, G.; Fiorina, P.; De Cobelli, F.; Scifo, P.; Esposito, A.; Canu, T.; Danna, M.; Gremizzi, C.; Secchi, A.;Luzi, L.; et al. Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation onresting left ventricular energy metabolism in type 1 diabetic-uremic patients: A phosphorous-31 magneticresonance spectroscopy study. J. Am. Coll. Cardiol. 2005, 46, 1085–1092. [CrossRef] [9] Simmons, K.M.; Michels, A.W. Type 1 diabetes: A predictable disease. World J. Diabetes 2015, 6, 380–390.[CrossRef] [10] Regnell, S.E.; Lernmark, A. Early prediction of autoimmune (type 1) diabetes. Diabetologia 2017, 60, 1370–1381.[CrossRef] [11] Di Lorenzo, T.P.; Peakman, M.; Roep, B.O. Translational mini-review series on type 1 diabetes: Systematicanalysis of T cell epitopes in autoimmune diabetes. Clin. Exp. Immunol. 2007, 148, 1–16. [CrossRef] [PubMed] [12] Wherrett, D.K.; Chiang, J.L.; Delamater, A.M.; DiMeglio, L.A.; Gitelman, S.E.; Gottlieb, P.A.; Herold, K.C.;Lovell, D.J.; Orchard, T.J.; Ryan, C.M.; et al. Defining pathways for development of disease-modifyingtherapies in children with type 1 diabetes: A consensus report. Diabetes Care 2015, 38, 1975–1985. [CrossRef]Laidlaw BJ, Craft JE, Kaech SM. The multifaceted role of CD4(+) T cells inCD8(+) T cell memory. Nat Rev Immunol (2016) 16:102–11. doi:10.1038/nri.2015.10 [13] Krummel MF, Bartumeus F, Gerard A. T cell migration, search strategies andmechanisms. Nat Rev Immunol (2016) 16:193–201. doi:10.1038/nri.2015.16 [14] Ettinger R, Kuchen S, Lipsky PE. The role of IL-21 in regulating B-cellfunction in health and disease. Immunol Rev (2008) 223:60–86. doi:10.1111/j.1600-065X.2008.00631.x [15] McGuire HM, Walters S, Vogelzang A, Lee CM, Webster KE, Sprent J, et al.Interleukin-21 is critically required in autoimmune and allogeneic responsesto islet tissue in murine models. Diabetes (2011) 60:867–75. doi:10.2337/db10-1157 [16] Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ. IL-21 signalingiscritical for the development of type I diabetes in the NOD mouse. ProcNatlAcadSci U S A (2008) 105:14028–33. doi:10.1073/pnas.0804358105 [17] Levine AG, Mendoza A, Hemmers S, Moltedo B, Niec RE, Schizas M, et al.Stability and function of regulatory T cells expressing the transcription factorT-bet. Nature (2017) 546:421–5. doi:10.1038/nature2236 [18] Eizenberg-Magar I, Rimer J, Zaretsky I, Lara-Astiaso D, Reich-ZeligerS,Friedman N. Diverse continuum of CD4(+) T-cell states is determined byhierarchical additive integration of cytokine signals. ProcNatlAcadSci U S A(2017) 114:E6447–56. doi:10.1073/pnas.161559011 [19] Bluestone JA, Mackay CR, O’Shea JJ, Stockinger B. The functional plasticity ofT cell subsets. Nat Rev Immunol (2009) 9:811–6. doi:10.1038/nri265 [20] Zhou L, Chong MMW, Littman DR. Plasticity of CD4(+) T cell lineage dif-ferentiation. Immunity (2009) 30:646–55. doi:10.1016/j.immuni.2009.05.00 [21] Das J, Ho M, Zikherman J, Govern C, Yang M, Weiss A, et al. Digital signalingand hysteresis characterize Ras activation in lymphoid cells. Cell (2009)136:337–51. doi:10.1016/j.cell.2008.11.051 [22] O’Garra A, Gabrysova L, Spits H. Quantitative events determine the differ-entiation and function of helper T cells. Nat Immunol (2011) 12:288–94.doi:10.1038/ni.2003 [23] Mayya V, Dustin ML. What scales the T cell response? Trends Immunol(2016) 37:513–22. doi:10.1016/j.it.2016.06.005 [24] Miossec P, Korn T, Kuchroo VK. Mechanisms of disease: interleukin-17and type 17 helper T cells. N Engl J Med (2009) 361:888–98. doi:10.1056/NEJMra0707449 [25] Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes (2011) 60:2903–13. doi:10.2337/db11-0090 [26] Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A, et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes (2009) 58:1302–11. doi:10.2337/db08-1113 [27] Miyara M, Ito Y, Sakaguchi S. TREG-cell therapies for autoimmune rheu-matic diseases. Nat Rev Rheumatol (2014) 10:543–51. doi:10.1038/nrrheum.2014.105 [28] Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol (2013) 9:92–103. doi:10.1038/nrendo.2012.237 [29] Herold KC, Vignali DAA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol(2013) 13:243–56. doi:10.1038/nri3422 [30] Roep BO, Tree TIM. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol (2014) 10:229–42. doi:10.1038/nrendo.2014.2 [31] Mohammadi MR, Nojoomi A, Mozafari M, Dubnika A, Inayathullah M, Rajadas J. Nanomaterials engineering for drug delivery: a hybridization approach. J Mater Chem B (2017) 5:3995–4018. doi:10.1039/C6TB03247H [32] Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med (2009) 360:1646–54. doi:10.1056/NEJMra0808284 [33] Ramsdell F, Ziegler SF. FOXP3 and scurfy: how it all began. Nat Rev Immunol(2014) 14:343–9. doi:10.1038/nri3650 [34] Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat Rev Immunol (2017) 17(11):703–17. doi:10.1038/nri.2017.75 [35] Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy (2016) 8:889–906. doi:10.2217/imt-2016-0049 [36] Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. ProcNatlAcadSci U S A (1994) 91:123–7. doi:10.1073/pnas.91.1.123

Copyright

Copyright © 2025 Miss. Renuka Raut, Miss. Sakshi Rathod, Mr. Rohit Sajjanshete, Mrs. Reshma Dhakate, Mr. Rahul Sanap, Mr. Vishwajeet Rohom. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.